LinkedIn · Nov 2024
Company post announcing the NSF SBIR Phase I grant and its focus on conditionally active protein medicines.
"If-then" conditional logic for protein drugs
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Biotechnology research startup founded in 2023, building conditional "if-then" protein therapeutics that activate only at diseased tissue and aim to improve the safety of cancer immunotherapies. Founders are brothers Elliot and Nathan Tague; the company was in Y Combinator Winter 2024. Public sources conflict slightly on HQ and funding totals (Cambridge vs. Somerville; roughly $500K-$625K reported), and I did not find a separate public CEO listing, careers page, GitHub, X, or engineering blog.
Primary product
Conditionally activated protein therapeutics ('if-then' gated protein medicines) for localized disease treatment
Founded
2023
Headquarters
Cambridge, Massachusetts, United States
Team size
1-10 employees
Industry
Biotechnology Research
Sub-industry
Protein therapeutics / drug discovery
Open Positions
0 jobs at SynsoryBio
No open positions
Check back later for new openings